Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $4.91 is 12.61% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 4.92||$ 15.20|
|Low:||$ 4.78||$ 4.36|
Company Description (as filed with the SEC)
We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat is a once-weekly, oral, small molecule, Class I HDAC inhibitor currently being evaluated in a Phase 3 clinical trial in combination with exemestane for advanced hormone receptor positive, or HR+, human epidermal growth factor receptor 2 negative, or HER2-, breast cancer, an indication for which it has been granted Breakthrough Therapy Designation by the FDA. Entinostat has been shown to block the function of immune suppressive cells in the tumor microenvironment, and is being evaluated in combination with several approved PD-1/PD-L1 antagonists, including in ongoing Phase 1b/2 clinical trials combining entinostat with Keytruda® from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with Tecentriq® from Genentech, Inc. ... More ...
Nasdaq Official Price
Dec. 14, 2018
Dec. 14, 2018